PDCD1 and bladder transitional cell carcinoma: Pembrolizumab and nivolumab targeting programmed cell death 1 (PD-1), and atezolizumab, avelumab and durvalumab targeting programmed death-ligand 1 (PD-L1) have been approved for the treatment of metastatic BLCA (14).